A randomized controlled trial assigns participants to comparison groups using a chance-based process. The purpose is to make a fairer comparison of outcomes. It is a powerful design, but the words “randomized trial” do not remove the need to examine how the study was conducted.

What does randomization do?

Random allocation helps reduce systematic differences between groups at the start. It does not guarantee that every characteristic is perfectly balanced, especially in small studies. The design also needs adequate protection against predicting assignments and against biased measurement or analysis.

Randomization is different from blinding. Randomization determines assignment; blinding limits who knows the assignment during the study. A trial may use one, both, or neither, depending on its design. NIH's overview explains why controlled comparisons matter when assessing whether an intervention works. NIH: Understanding Clinical Studies

What is a placebo-controlled study?

A placebo comparator is designed to resemble the study intervention without its specific active component. It can help distinguish effects of the active intervention from changes associated with expectations, participation, or the course of a condition. Not every trial should use a placebo: ethical and scientific considerations may require comparison with an established treatment or another design. NIH/NCATS: Placebo; CIOMS/WHO: Choice of Control in Clinical Trials

The key is not that a placebo group makes a study automatically convincing. The comparison must suit the question, and the outcomes must be assessed well.

What is a clinical endpoint?

An endpoint is the precisely defined outcome used to evaluate the research question. It includes what is measured and when, and may include how the measurement is analyzed. Outcomes can concern how a person feels, functions, or survives, or can use another measure intended to stand in for clinical benefit.

A surrogate endpoint is a substitute measure. Its usefulness depends on evidence that changes in that measure predict the outcome of interest in the relevant context. A laboratory marker does not become a validated surrogate merely because it is easy to measure. FDA: Basics of Clinical Trial Design

Read the endpoint before the headline

Suppose an article says an intervention “improved health,” but the trial measured only a short-term biomarker. The study may have found a real biological effect while the headline goes beyond it. Ask whether the reported improvement is meaningful to participants, how large it was, how long it lasted, and what harms were observed.

A strong interpretation describes the comparison and endpoint together. “Better than placebo on a specific measure at a specific time” is more informative than an unqualified claim that something works.